Hsbc Holdings PLC Takes $753,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH

Hsbc Holdings PLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 38,017 shares of the company’s stock, valued at approximately $753,000.

Several other large investors have also recently added to or reduced their stakes in the business. TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 1.6% in the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock worth $52,571,000 after buying an additional 31,160 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Amphastar Pharmaceuticals by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,799,685 shares of the company’s stock valued at $48,196,000 after acquiring an additional 44,020 shares during the last quarter. State Street Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 2.1% during the 4th quarter. State Street Corp now owns 1,531,786 shares of the company’s stock worth $41,021,000 after acquiring an additional 31,044 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after acquiring an additional 40,536 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after acquiring an additional 363,216 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on AMPH. Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Finally, Bank of America restated an “underperform” rating and set a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $22.00.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $20.58 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $16.65 and a 1-year high of $31.26. The firm has a market capitalization of $907.37 million, a P/E ratio of 12.40, a P/E/G ratio of 4.25 and a beta of 0.89. The business’s 50-day simple moving average is $19.46 and its 200-day simple moving average is $21.72.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The business had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.